Over $20M Bet On This Healthcare Stock? Check Out These 3 Stocks Insiders Are Buying
Over $20M Bet On This Healthcare Stock? Check Out These 3 Stocks Insiders Are Buying
Although U.S. stocks closed higher on Wednesday, there were a few notable insider trades.
儘管美國股市週三收高，但仍有一些值得注意的內幕交易。
When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision.
當內部人士購買股票時，這表明他們對公司前景充滿信心，或者他們認爲股票很划算。無論哪種方式，這都預示着做多該股的機會。不應將內幕購買視爲做出投資或交易決策的唯一指標。充其量，它可以爲購買決定提供信心。
Below is a look at a few recent notable insider purchases. For more, check out Benzinga's insider transactions platform.
以下是最近一些值得注意的內幕收購。欲了解更多，請查看 本辛加的內幕交易 平台。
SunOpta
sunOpta
- The Trade: SunOpta Inc. (NASDAQ:STKL) CEO Brian W Kocher acquired a total of 38,000 shares an average price of $6.65. To acquire these shares, it cost around $252,757.
- What's Happening: On Feb. 28, SunOpta posted upbeat quarterly earnings.
- What SunOpta Does: SunOpta Inc is a Canadian company that focuses on a healthy product portfolio.
- 交易：SunOpta Inc.（納斯達克股票代碼：STKL）首席執行官布萊恩·科徹 共收購了38,000股股票 平均價格爲6.65美元。收購這些股票的成本約爲252,757美元。
- 發生了什麼：2月28日，SunOpta公佈了樂觀的季度收益。
- SunOpta做什麼：SunOpta Inc是一家加拿大公司，專注於健康的產品組合。
89bio
89bio
- The Trade: 89bio, Inc. (NASDAQ:ETNB) Director Rajeev Shah acquired a total of 1,350,000 shares at an average price of $15.35. To acquire these shares, it cost around $20.72 million.
- What's Happening: On Feb. 29, 89bio posted a wider-than-expected quarterly loss.
- What 89bio Does: 89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases.
- 交易：89bio, Inc.（納斯達克股票代碼：ETNB）董事拉傑夫·沙阿共收購了135萬股股票，平均價格爲15.35美元。收購這些股票的成本約爲2072萬美元。
- 發生了什麼：2月29日，89bio公佈的季度虧損超出預期。
- 89bio做什麼：89bio Inc是一家總部位於美國的臨床階段生物製藥公司，專注於肝臟和心臟代謝疾病治療療法的開發和商業化。
Don't forget to check out our premarket coverage here
別忘了在這裏查看我們的上市前報道
IonQ
ionQ
- The Trade: IonQ, Inc. (NYSE:IONQ) Director Harry L. You bought a total of 115,000 shares at an average price of $9.28. To acquire these shares, it cost around $1.07 million.
- What's Happening: On Feb 28, IonQ reported second-quarter revenue of $6.11 million, which beat the consensus estimate of $5.76 million.
- What IonQ Does: IonQ Inc sells access to several quantum computers of various qubit capacities and is in the process of researching and developing technologies for quantum computers with increasing computational capabilities.
- 交易：ionQ, Inc.（紐約證券交易所代碼：IONQ）董事 Harry L. You 共購買了 115,000 股股票 平均價格爲9.28美元。收購這些股票的成本約爲107萬美元。
- 發生了什麼：2月28日，IonQ公佈的第二季度收入爲611萬美元，超過了市場普遍預期的576萬美元。
- ionQ 做什麼：ionQ Inc 出售幾臺不同量子比特容量的量子計算機的訪問權限，並且正在研究和開發計算能力不斷增強的量子計算機技術。
Check This Out: Cramer: This REIT Is 'A Little Too Dicey'; As For Marathon Digital, 'Own The Pure'
看看這個： 克萊默：這個房地產投資信託基金 “有點太糟糕了”；至於 Marathon Digital，“Own The Pure”
譯文內容由第三人軟體翻譯。